The implication of these abnormalities in the rewarding properties exhibited by L-Dopa in the PD model suggests that therapeutic approaches targeting excessive D1R-mediated transmission may be beneficial for the treatment of DDS. The gene discussed is DRD1; the disease is Denys-Drash syndrome.